Latest Multiple Myeloma Research Consortium Stories
SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation (MMRF) today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor.
S. 3988/A. 6233 will ensure that health plans already providing insurance coverage for chemotherapy will provide equal coverage for both IV/injected and oral therapies.
CALGARY, May 10 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S.
SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
RYE, N.Y., Dec. 13, 2010 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, has appointed Jennifer Katritos, CPA, as vice president of finance, the company announced. She joined Curemark in July, 2009 as director of finance.
In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec.
A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients.
In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.